Carvedilol Effect in Preventing Chemotherapy - Induced Cardiotoxicity

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 200 participants.

Also called NCT01724450

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose prevention
Phase
Phase 3
Enrolled
  • 200 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01724450
Other papers using this trial's data
  • Carvedilol for Prevention of Chemotherapy-Related Cardiotoxicity: The CECCY Trial Journal of the American College of Cardiology, 2018-05-22 DOI, PubMed 29540327

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Brazil (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01724450. Randomized; quadruple masking; primary purpose prevention. Start 2013-04 (actual); primary completion 2017-06 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Carvedilol Effect in Preventing Chemotherapy - Induced Cardiotoxicity
Acronym
Ceccy
Condition
Breast Cancer
Condition
Heart Failure
Condition
Cardiotoxicity
Intervention (Drug)
Carvedilol
Intervention (Drug)
Placebo
Lead sponsor
University of Sao Paulo (class: other)
Collaborator
Hospital A.C. Camargo (class: other)
Collaborator
Instituto do Cancer do Estado de São Paulo (class: other)

Record details

Record id
cardio:ct-nct01724450
Content hash
5322f458c291294c530e4b907cbc79a75ac7468001f41f79705bd700284110a8